<DOC>
	<DOCNO>NCT03050047</DOCNO>
	<brief_summary>A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study Pharmacokinetics , Pharmacodynamics , Safety , Immunogenicity BCD-100 ( JSC BIOCAD , Russia ) Patients Advanced Solid Tumors</brief_summary>
	<brief_title>A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study BCD-100 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>1 . Patient provide write informed consent able follow requirement Protocol ; 2 . Age ≥ 18 year 3 . Histologically confirmed cancer ( welldocumented test result ; preferably , block specimen available ) : unresectable ( stage III/IV ) metastatic ( stage IV ) melanoma ( drug use first subsequent therapy line ) ; Locally advance metastatic NSCLC ( squamous cell carcinoma/adenocarcinoma ) , progressive least firstline therapy ( drug use second subsequent therapy line ) ; Metastatic clear cell renal carcinoma , progressive least firstline therapy ( drug use second subsequent therapy line ) ; In addition , investigator 's decision , patient follow malignancy also enrol study : Pleural mesothelioma progressive least one therapy line ( drug use second subsequent therapy line ) ; Metastatic bladder cancer progressive least one therapy line ( drug use second subsequent therapy line ) ; Triple negative breast cancer ( ER , PR , HER2 ) progressive least firstline therapy ( drug use second subsequent therapy line ) ; 4 . ECOG score 0 2 ; 5 . Measurable disease ( least one lesion ) accord RECIST v. 1.1 ; 6 . Resolved toxicity event previous therapy adverse consequence surgical intervention ≤ grade 1 CTCAE v. 4.03 , except chronic/irreversible adverse event affect safety study therapy ( e.g . alopecia ) ; 7 . No severe pathology organ system ; 8 . Life expectancy least 12 week screen ; 9 . Patients childbearing potential enrol study must agree use reliable contraception method throughout study period , begin 2 week inclusion study 8 week last dose BCD100 . 1 . Severe concomitant illness lifethreatening consequence ( include pleural/pericardial/peritoneal effusion require medical intervention , pulmonary lymphangitis , involvement &gt; 50 % renal parenchyma ) ; 2 . Brain metastasis , progressive associate clinical symptom ( e.g . cerebral edema spinal cord compression ) . Exclusions : metastasis progress require steroid and/or anticonvulsant within least 4 week randomization ; 3 . Severe cardiovascular disorder within 6 month screen ; 4 . Autoimmune diseases ; 5 . Conditions require steroid immunosuppressant ; 6 . Blood disorder : ANC ≤1,500/mm3 ; platelet ≤100,000/mm3 ; Hb ≤90 g/L ; 7 . Renal function impairment : creatinine ≥1.5 × ULN ; 8 . Hepatic function impairment : bilirubin ≥1.5 × ULN ; AST ALT ≥2.5 × ULN ( 5 × ULN patient liver metastasis ) , AlkPh ≥ 5 × ULN ; 9 . Prior anticancer treatment within 28 day start study drug ( surgery , radiation therapy , chemotherapy ) ; 10 . Known history 6 line systemic anticancer chemotherapy ( include neoadjuvant adjuvant CTs ) ; 11 . Prior treatment antiPD1/PDL1 agent CTLA4 inhibitor ; 12 . Concurrent malignancy except radically resect cervical carcinoma situ radically resect basal cell/squamous cell carcinoma ; 13 . Conditions limit patient 's ability follow Protocol requirement ( dementia , neurological psychiatric disorder , drug alcohol abuse , etc . ) ; 14 . Simultaneous participation clinical trial ; participation clinical trial within 30 day inclusion present study ; previous participation present study . 15 . Acute infection active chronic infection ; 16 . Documented HIV infection ; 17 . Positive screening result Hbsantigen , hepatitis B core antibody ( antiHBc Ab ) and/or hepatitis C antibodies ; 18 . Positive result microprecipitation reaction together positive TPHA assay result screen ; 19 . Body weight &gt; 95 kg . 20 . Intravenous administration drug impossible ; 21 . Intravenous administration contrast agent impossible ; 22 . Hypersensitivity component BCD100 . 23 . Known history hypersensitivity monoclonal antibody ; 24 . Pregnancy breastfeeding ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>